Flutemetamol (18F) 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4301 765922-62-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Flutemetamol (18F)
  • 18F-Flutemetamol
  • flutemetamol F 18 injection
  • flutemetamol F 18
  • vizamyl
  • flutemetamol F18
  • flutemetamol F-18
used for PET imaging of brain fibrillar amyloid beta
  • Molecular weight: 273.32
  • Formula: C14H11FN2OS
  • CLOGP: 4.30
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 45.15
  • ALOGS: -4.31
  • ROTB: 2

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 2017 PMDA Nihon Medi-Physics Co Ltd
Oct. 25, 2013 FDA GE HEALTHCARE
Aug. 22, 2014 EMA GE Healthcare AS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V09AX04 VARIOUS
DIAGNOSTIC RADIOPHARMACEUTICALS
CENTRAL NERVOUS SYSTEM
Other central nervous system diagnostic radiopharmaceuticals
FDA MoA N0000000205 Radiopharmaceutical Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
MeSH PA D007202 Indicators and Reagents
MeSH PA D019275 Radiopharmaceuticals
FDA EPC N0000177914 Radioactive Diagnostic Agent
CHEBI has role CHEBI:37336 radioactive imaging agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Positron emission tomography indication 82918005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.2 acidic
pKa2 3.58 Basic
pKa3 2.7 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
121.5mCi/30ML (4.05mCi/ML) VIZAMYL GE HEALTHCARE N203137 Oct. 25, 2013 RX INJECTABLE INTRAVENOUS 7351401 Jan. 24, 2023 DIAGNOSTIC RADIOIMAGING
121.5mCi/30ML (4.05mCi/ML) VIZAMYL GE HEALTHCARE N203137 Oct. 25, 2013 RX INJECTABLE INTRAVENOUS 8691185 Jan. 24, 2023 DIAGNOSTIC RADIOIMAGING
40.5mCi/10ML (4.05mCi/ML) VIZAMYL GE HEALTHCARE N203137 Oct. 25, 2013 DISCN INJECTABLE INTRAVENOUS 7351401 Jan. 24, 2023 DIAGNOSTIC RADIOIMAGING
40.5mCi/10ML (4.05mCi/ML) VIZAMYL GE HEALTHCARE N203137 Oct. 25, 2013 DISCN INJECTABLE INTRAVENOUS 8691185 Jan. 24, 2023 DIAGNOSTIC RADIOIMAGING
121.5mCi/30ML (4.05mCi/ML) VIZAMYL GE HEALTHCARE N203137 Oct. 25, 2013 RX INJECTABLE INTRAVENOUS 7270800 Sept. 3, 2025 DIAGNOSTIC RADIOIMAGING
40.5mCi/10ML (4.05mCi/ML) VIZAMYL GE HEALTHCARE N203137 Oct. 25, 2013 DISCN INJECTABLE INTRAVENOUS 7270800 Sept. 3, 2025 DIAGNOSTIC RADIOIMAGING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amyloid beta A4 protein Unclassified Ki 9.15 CHEMBL

External reference:

IDSource
D10231 KEGG_DRUG
4038255 VANDF
C2983948 UMLSCUI
CHEBI:76611 CHEBI
CHEMBL2042122 ChEMBL_ID
DB09151 DRUGBANK_ID
C581552 MESH_SUPPLEMENTAL_RECORD_UI
15950376 PUBCHEM_CID
1486025 RXNORM
206870 MMSL
29778 MMSL
d08135 MMSL
016452 NDDF
456996004 SNOMEDCT_US
456997008 SNOMEDCT_US
9169 INN_ID
L49M066S0O UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vizamyl HUMAN PRESCRIPTION DRUG LABEL 1 17156-067 SOLUTION 4.05 mCi INTRAVENOUS NDA 26 sections
Vizamyl HUMAN PRESCRIPTION DRUG LABEL 1 17156-067 SOLUTION 4.05 mCi INTRAVENOUS NDA 26 sections
Vizamyl HUMAN PRESCRIPTION DRUG LABEL 1 17156-067 SOLUTION 4.05 mCi INTRAVENOUS NDA 26 sections
Vizamyl HUMAN PRESCRIPTION DRUG LABEL 1 17156-067 SOLUTION 4.05 mCi INTRAVENOUS NDA 26 sections